Post-marketing evaluation of the short term safety of COMVAX®

Vaccine

Volumn 22, Issue 3-4, 2004, Pages 536-543

  Davis, Robert L ^a   Black, Steven ^b   Shinefield, Henry ^b   Mahoney, Lisa ^a   Zavitkovsky, Ann ^a   Lewis, Edwin ^b   Nikas, Alex ^c   Guess, Harry ^c   Coplan, Paul ^c  

^a CENTER FOR HEALTH STUDIES   (United States)

^b KAISER PERMANENTE   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

COMVAX; Post marketing; Vaccine safety

Indexed keywords

CHICKENPOX VACCINE; DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; INFLUENZA VACCINE; LIQUID PEDVAXHIB; M M R II; RECOMBINANT HEPATITIS B VACCINE; VACCINE;

ADULT; ARTICLE; BRONCHIOLITIS; BRONCHITIS; CALCULATION; CHILD; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DATA BASE; DIARRHEA; DRUG FATALITY; DRUG MARKETING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EMERGENCY WARD; ENTERITIS; EXTRINSIC ASTHMA; FEMALE; FEVER; GASTROENTERITIS; GASTROINTESTINAL SYMPTOM; HEPATITIS B; HOSPITALIZATION; HUMAN; INFANT; INFLUENZA; INFLUENZA VACCINATION; INFORMATION PROCESSING; INTRINSIC ASTHMA; NAUSEA; NORMAL HUMAN; OUTPATIENT DEPARTMENT; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; RISK FACTOR; SIDE EFFECT; STATISTICAL SIGNIFICANCE; VOMITING; WHEEZING;

EID: 0345528126     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2003.06.001     Document Type: Article

References (7)

1. Progress toward elimination of haemophilus influenzae type b disease among infants and children - United States, 1987-1995. MMWR 1996;45:901-906.
2. Hepatitis Prevention through universal childhood vaccination: recommendations of the immunization practices advisory committee (ACIP). MMWR 1991;40:1-19.
3. Merck and Co, Inc. postmarketing study for PedvaxHIB® in infants and older children at southern California Kaiser: final study report to CBER. March 31, 1995.
4. Davis R.L., Black S., Vadheim C.et al. Immunization tracking systems: experience of the CDC Vaccine Safety Datalink sites. HMO Pract. 11:1997;13-17.
5. Miettinen O., Nurminen M. Comparative analysis of two rates. Stat. Med. 4:1985;213-226.
6. Guess H.A., Lydick E.G., Small R.D.et al. Epidemiologic programs for computers and calculators. Exact binomial confidence intervals for the relative risk in follow-up studies with sparsely stratified incidence density data. Am. J. Epidemiol. 125:1987;340-347.
7. Black S., Shinefield H., Ray P.et al. Postmarketing evaluation of the safety and effectiveness of varicella vaccine. Pediatr. Infect. Dis. J. 18:1999;1041-1046.